AU2022271191A1 - Lactoyl amino acids for the treatment of metabolic disease - Google Patents

Lactoyl amino acids for the treatment of metabolic disease Download PDF

Info

Publication number
AU2022271191A1
AU2022271191A1 AU2022271191A AU2022271191A AU2022271191A1 AU 2022271191 A1 AU2022271191 A1 AU 2022271191A1 AU 2022271191 A AU2022271191 A AU 2022271191A AU 2022271191 A AU2022271191 A AU 2022271191A AU 2022271191 A1 AU2022271191 A1 AU 2022271191A1
Authority
AU
Australia
Prior art keywords
lac
phe
lactoyl
subject
exercise
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022271191A
Other languages
English (en)
Inventor
Steven BANIK
Yang He
Veronica LI
Jonathan Long
Yong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Leland Stanford Junior University
Original Assignee
Baylor College of Medicine
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Leland Stanford Junior University filed Critical Baylor College of Medicine
Publication of AU2022271191A1 publication Critical patent/AU2022271191A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2022271191A 2021-05-04 2022-05-02 Lactoyl amino acids for the treatment of metabolic disease Pending AU2022271191A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183868P 2021-05-04 2021-05-04
US63/183,868 2021-05-04
PCT/US2022/027261 WO2022235557A1 (en) 2021-05-04 2022-05-02 Lactoyl amino acids for the treatment of metabolic disease

Publications (1)

Publication Number Publication Date
AU2022271191A1 true AU2022271191A1 (en) 2023-11-02

Family

ID=83932803

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022271191A Pending AU2022271191A1 (en) 2021-05-04 2022-05-02 Lactoyl amino acids for the treatment of metabolic disease

Country Status (7)

Country Link
US (1) US20240189266A1 (https=)
EP (1) EP4313297A4 (https=)
JP (1) JP2024516969A (https=)
KR (1) KR20240006050A (https=)
CN (1) CN117769414A (https=)
AU (1) AU2022271191A1 (https=)
WO (1) WO2022235557A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240122888A1 (en) * 2022-10-03 2024-04-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of phenylalanine and lactate
CN116035217B (zh) * 2022-12-23 2023-08-04 暨南大学 一种具有减肥减脂作用的组合物与应用
WO2024192165A1 (en) * 2023-03-14 2024-09-19 The Board Of Trustees Of The Leland Stanford Junior University N-beta-hydroxybutyryl-amino acids and related compositions and methods
WO2025072489A2 (en) * 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
WO2025184353A1 (en) * 2024-03-01 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating metabolic disorders
CN118795011B (zh) * 2024-06-28 2025-01-21 合肥工业大学 一种用于细胞代谢产物n-l-乳酰-l-苯丙氨酸的快速检测方法
CN119350175B (zh) * 2024-10-15 2026-03-17 广东药科大学 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159146A (zh) * 1995-07-26 1997-09-10 弗门尼舍有限公司 风味产品及其制备方法
AU719332B2 (en) * 1995-09-19 2000-05-04 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
WO2012054528A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies

Also Published As

Publication number Publication date
CN117769414A (zh) 2024-03-26
WO2022235557A1 (en) 2022-11-10
US20240189266A1 (en) 2024-06-13
EP4313297A4 (en) 2024-09-18
EP4313297A1 (en) 2024-02-07
JP2024516969A (ja) 2024-04-18
KR20240006050A (ko) 2024-01-12

Similar Documents

Publication Publication Date Title
US20240189266A1 (en) Lactoyl Amino Acids for the Treatment of Metabolic Disease
Zhang et al. Intestinal AMPK modulation of microbiota mediates crosstalk with brown fat to control thermogenesis
Xu et al. Cholesterol sulfate alleviates ulcerative colitis by promoting cholesterol biosynthesis in colonic epithelial cells
Yuan et al. Exercise‐induced α‐ketoglutaric acid stimulates muscle hypertrophy and fat loss through OXGR1‐dependent adrenal activation
Cuadrado et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Tezze et al. Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence
Wu et al. Metformin protects against LPS-induced intestinal barrier dysfunction by activating AMPK pathway
Binder et al. Leucine supplementation protects from insulin resistance by regulating adiposity levels
Labbé et al. mTORC1 is required for brown adipose tissue recruitment and metabolic adaptation to cold
Zhang et al. Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway
Yeh et al. Hesperetin promotes longevity and delays aging via activation of Cisd2 in naturally aged mice
Zhang et al. Protective effects of chlorogenic acid on the meat quality of oxidatively stressed broilers revealed by integrated metabolomics and antioxidant analysis
Huang et al. M2 macrophages secrete glutamate-containing extracellular vesicles to alleviate osteoporosis by reshaping osteoclast precursor fate
Mao et al. Ferroptosis: a potential bridge linking gut microbiota and chronic kidney disease
Zheng et al. Carbon monoxide-releasing molecules reverse leptin resistance induced by endoplasmic reticulum stress
Khalyfa et al. Activation of the integrated stress response and metabolic dysfunction in a murine model of sleep apnea
Zhou et al. Targeting gut S. aureofaciens Tü117 serves as a new potential therapeutic intervention for the prevention and treatment of hypertension
Ma et al. HDAC5-mTORC1 interaction in differential regulation of ghrelin and nucleobindin 2 (NUCB2)/nesfatin-1
Yin et al. Nucleolin promotes autophagy through PGC-1α in LPS-induced myocardial injury
EP4680222A1 (en) N-beta-hydroxybutyryl-amino acids and related compositions and methods
Jang et al. Free essential amino acid feeding improves endurance during resistance training via DRP1‐dependent mitochondrial remodelling
Lin et al. Homocysitaconate controls inflammation through reshaping methionine metabolism and N-homocysteinylation
La Spina et al. Multiple mechanisms converging on transcription factor EB activation by the natural phenol pterostilbene
Liu et al. Hesperidin improves cardiac fibrosis induced by β-adrenergic activation through modulation of gut microbiota
Liu et al. 3-Fucosyllactose Prevents Nonalcoholic Fatty Liver Disease by Modulating the Gut Microbiota-Derived Pantothenate in Mice